Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response.
Seifert LL, Si C, Saha D, Sadic M, de Vries M, Ballentine S, Briley A, Wang G, Valero-Jimenez AM, Mohamed A, Schaefer U, Moulton HM, García-Sastre A, Tripathi S, Rosenberg BR, Dittmann M. Seifert LL, et al. Among authors: dittmann m. PLoS Pathog. 2019 Nov 4;15(11):e1007634. doi: 10.1371/journal.ppat.1007634. eCollection 2019 Nov. PLoS Pathog. 2019. PMID: 31682641 Free PMC article.
A comparative study of in vitro air-liquid interface culture models of the human airway epithelium evaluating cellular heterogeneity and gene expression at single cell resolution.
Prescott RA, Pankow AP, de Vries M, Crosse KM, Patel RS, Alu M, Loomis C, Torres V, Koralov S, Ivanova E, Dittmann M, Rosenberg BR. Prescott RA, et al. Among authors: dittmann m. Respir Res. 2023 Aug 28;24(1):213. doi: 10.1186/s12931-023-02514-2. Respir Res. 2023. PMID: 37635251 Free PMC article.
Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.
Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, Rajsbaum R, Menachery VD. Lokugamage KG, et al. Among authors: dittmann m. bioRxiv [Preprint]. 2020 Jul 13:2020.03.07.982264. doi: 10.1101/2020.03.07.982264. bioRxiv. 2020. PMID: 32511335 Free PMC article. Updated. Preprint.
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.
Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, Rajsbaum R, Menachery VD. Lokugamage KG, et al. Among authors: dittmann m. J Virol. 2020 Nov 9;94(23):e01410-20. doi: 10.1128/JVI.01410-20. Print 2020 Nov 9. J Virol. 2020. PMID: 32938761 Free PMC article.
Identification of a nerve-associated, lung-resident interstitial macrophage subset with distinct localization and immunoregulatory properties.
Ural BB, Yeung ST, Damani-Yokota P, Devlin JC, de Vries M, Vera-Licona P, Samji T, Sawai CM, Jang G, Perez OA, Pham Q, Maher L, Loke P, Dittmann M, Reizis B, Khanna KM. Ural BB, et al. Among authors: dittmann m. Sci Immunol. 2020 Mar 27;5(45):eaax8756. doi: 10.1126/sciimmunol.aax8756. Sci Immunol. 2020. PMID: 32220976 Free PMC article.
A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A, Schinlever A, Loose P, Ruggles K, Koralov SB, Anderson AS, Binder J, Dittmann M. de Vries M, et al. Among authors: dittmann m. bioRxiv [Preprint]. 2021 Feb 19:2020.08.28.272880. doi: 10.1101/2020.08.28.272880. bioRxiv. 2021. PMID: 32869028 Free PMC article. Updated. Preprint.
A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A, Schinlever A, Loose P, Ruggles K, Koralov SB, Anderson AS, Binder J, Dittmann M. de Vries M, et al. Among authors: dittmann m. J Virol. 2021 Mar 10;95(7):e01819-20. doi: 10.1128/JVI.01819-20. Epub 2021 Feb 23. J Virol. 2021. PMID: 33622961 Free PMC article.
132 results